Product Details

Evenity

Romosozumab
105 mg/1.17 mL (90 mg/mL)
Solution for Subcutaneous Injection
1.17-mL Single-Use Prefilled Syringe (Preservative-Free)

DIN/PIN/NPN

02489597

Manufacturer

Amgen Canada Inc.

Formulary Listing Date

2026-01-30  

Unit Price

359.4350

Amount MOH Pays

359.4350

Coverage Status

Exceptional Access Program Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

M05BX06

Interchangeable Products

NO  

LU Clinical Criteria

NO  

Requirements


EAP Criteria

 
Therapeutic Class Reimbursement Criteria
Osteoporosis

Romosozumab

  • Brand(s): Evenity
  • Dosage Form/Strength: 90 mg/mL pre-filled syringe
  • Effective date: October 11, 2023

For the treatment of osteoporosis in postmenopausal women meeting ALL the following criteria:

  1. History of osteoporotic fracture;
    AND
  2. Is at a high risk for future fracture, defined as a 10-year fracture risk greater than or equal to 20% as defined by the Fracture Risk Assessment (FRAX) Tool;
    AND
  3. Treatment naive to osteoporosis medications, except for calcium and/or vitamin D.

Exclusion criteria:

Romosozumab will not be funded as combination therapy with other osteoporosis medications, except for calcium and/or vitamin D.

Recommended dose:

210 mg subcutaneously once every month for 12 doses

Approval duration: 12 months (A maximum of 12 monthly doses will be reimbursed.)

Renewals will not be considered.

Note: Requesting prescriber must include a copy of the FRAX assessment.

Product Monograph

View Monograph